Cancer Platform

cancerAllachem has been developing novel small molecules with improved pharmacokinetics, efficacy, and safety properties as compared to competitors’ first in class compounds.

Allachem’s drug candidate ONC1-13B is now in clinical development for prostate cancer. This substance possesses excellent DMPK/tox. ONC2-13B is now in pre-clinical development.

Download ONC1-13B – a New Effective Anti-Androgen for the Treatment of Prostate and Breast Cancers Documentation